Literature DB >> 19949037

A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking.

C E Teunissen1, A Petzold, J L Bennett, F S Berven, L Brundin, M Comabella, D Franciotta, J L Frederiksen, J O Fleming, R Furlan, R Q Hintzen, S G Hughes, M H Johnson, E Krasulova, J Kuhle, M C Magnone, C Rajda, K Rejdak, H K Schmidt, V van Pesch, E Waubant, C Wolf, G Giovannoni, B Hemmer, H Tumani, F Deisenhammer.   

Abstract

There is a long history of research into body fluid biomarkers in neurodegenerative and neuroinflammatory diseases. However, only a few biomarkers in CSF are being used in clinical practice. One of the most critical factors in CSF biomarker research is the inadequate powering of studies because of the lack of sufficient samples that can be obtained in single-center studies. Therefore, collaboration between investigators is needed to establish large biobanks of well-defined samples. Standardized protocols for biobanking are a prerequisite to ensure that the statistical power gained by increasing the numbers of CSF samples is not compromised by preanalytical factors. Here, a consensus report on recommendations for CSF collection and biobanking is presented, formed by the BioMS-eu network for CSF biomarker research in multiple sclerosis. We focus on CSF collection procedures, preanalytical factors, and high-quality clinical and paraclinical information. The biobanking protocols are applicable for CSF biobanks for research targeting any neurologic disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19949037      PMCID: PMC2839806          DOI: 10.1212/WNL.0b013e3181c47cc2

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  45 in total

1.  PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS.

Authors:  G A SCHUMACHER; G BEEBE; R F KIBLER; L T KURLAND; J F KURTZKE; F MCDOWELL; B NAGLER; W A SIBLEY; W W TOURTELLOTTE; T L WILLMON
Journal:  Ann N Y Acad Sci       Date:  1965-03-31       Impact factor: 5.691

2.  Discontinuous distribution of IgG oligoclonal bands in cerebrospinal fluid from multiple sclerosis patients.

Authors:  G Martino; L M Grimaldi; L Moiola; M Filippi; V Martinelli; G Comi; N Canal
Journal:  J Neuroimmunol       Date:  1990-12       Impact factor: 3.478

3.  Age-related changes in cerebrospinal fluid protein concentrations.

Authors:  M J Garton; G Keir; M V Lakshmi; E J Thompson
Journal:  J Neurol Sci       Date:  1991-07       Impact factor: 3.181

4.  Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity.

Authors:  R H S R Roxburgh; S R Seaman; T Masterman; A E Hensiek; S J Sawcer; S Vukusic; I Achiti; C Confavreux; M Coustans; E le Page; G Edan; G V McDonnell; S Hawkins; M Trojano; M Liguori; E Cocco; M G Marrosu; F Tesser; M A Leone; A Weber; F Zipp; B Miterski; J T Epplen; A Oturai; P Soelberg Sørensen; E G Celius; N Téllez Lara; X Montalban; P Villoslada; A M Silva; M Marta; I Leite; B Dubois; J Rubio; H Butzkueven; T Kilpatrick; M P Mycko; K W Selmaj; M E Rio; M Sá; G Salemi; G Savettieri; J Hillert; D A S Compston
Journal:  Neurology       Date:  2005-04-12       Impact factor: 9.910

5.  Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group.

Authors:  Melissa K Tuck; Daniel W Chan; David Chia; Andrew K Godwin; William E Grizzle; Karl E Krueger; William Rom; Martin Sanda; Lynn Sorbara; Sanford Stass; Wendy Wang; Dean E Brenner
Journal:  J Proteome Res       Date:  2009-01       Impact factor: 4.466

Review 6.  Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report.

Authors:  M Andersson; J Alvarez-Cermeño; G Bernardi; I Cogato; P Fredman; J Frederiksen; S Fredrikson; P Gallo; L M Grimaldi; M Grønning
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-08       Impact factor: 10.154

Review 7.  Development of biomarkers in multiple sclerosis.

Authors:  Bibiana Bielekova; Roland Martin
Journal:  Brain       Date:  2004-06-04       Impact factor: 13.501

8.  Stability of interleukin 6, soluble interleukin 6 receptor, interleukin 10 and CC16 in human serum.

Authors:  Gunter Kenis; Charlotte Teunissen; Raf De Jongh; Eugène Bosmans; Harry Steinbusch; Michael Maes
Journal:  Cytokine       Date:  2002-09-07       Impact factor: 3.861

9.  Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.

Authors:  W I McDonald; A Compston; G Edan; D Goodkin; H P Hartung; F D Lublin; H F McFarland; D W Paty; C H Polman; S C Reingold; M Sandberg-Wollheim; W Sibley; A Thompson; S van den Noort; B Y Weinshenker; J S Wolinsky
Journal:  Ann Neurol       Date:  2001-07       Impact factor: 10.422

10.  Intercenter agreement of brain atrophy measurement in multiple sclerosis patients using manually-edited SIENA and SIENAX.

Authors:  Bas Jasperse; Paola Valsasina; Veronica Neacsu; Dirk L Knol; Nicola De Stefano; Christian Enzinger; Stephen M Smith; Stefan Ropele; Tijmen Korteweg; Antonio Giorgio; Valerie Anderson; Chris H Polman; Massimo Filippi; David H Miller; Marco Rovaris; Frederik Barkhof; Hugo Vrenken
Journal:  J Magn Reson Imaging       Date:  2007-10       Impact factor: 4.813

View more
  230 in total

Review 1.  Cerebrospinal fluid biomarker candidates of schizophrenia: where do we stand?

Authors:  Nenad Vasic; Bernhard J Connemann; Robert C Wolf; Hayrettin Tumani; Johannes Brettschneider
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-12-16       Impact factor: 5.270

Review 2.  Proteomics and systems biology: current and future applications in the nutritional sciences.

Authors:  J Bernadette Moore; Mark E Weeks
Journal:  Adv Nutr       Date:  2011-06-28       Impact factor: 8.701

3.  Standardizing the structure of stroke clinical and epidemiologic research data: the National Institute of Neurological Disorders and Stroke (NINDS) Stroke Common Data Element (CDE) project.

Authors:  Jeffrey L Saver; Steven Warach; Scott Janis; Joanne Odenkirchen; Kyra Becker; Oscar Benavente; Joseph Broderick; Alexander W Dromerick; Pamela Duncan; Mitchell S V Elkind; Karen Johnston; Chelsea S Kidwell; James F Meschia; Lee Schwamm
Journal:  Stroke       Date:  2012-02-02       Impact factor: 7.914

Review 4.  Body fluid biomarkers for multiple sclerosis--the long road to clinical application.

Authors:  Charlotte E Teunissen; Arjan Malekzadeh; Cyra Leurs; Claire Bridel; Joep Killestein
Journal:  Nat Rev Neurol       Date:  2015-09-22       Impact factor: 42.937

5.  Analytical and clinical performances of the automated Lumipulse cerebrospinal fluid Aβ42 and T-Tau assays for Alzheimer's disease diagnosis.

Authors:  Jean-Louis Bayart; Bernard Hanseeuw; Adrian Ivanoiu; Vincent van Pesch
Journal:  J Neurol       Date:  2019-06-10       Impact factor: 4.849

Review 6.  Proteomic analyses of CSF aimed at biomarker development for pediatric brain tumors.

Authors:  Nardin Samuel; Marc Remke; James T Rutka; Brian Raught; David Malkin
Journal:  J Neurooncol       Date:  2014-04-26       Impact factor: 4.130

7.  High performance liquid chromatography determination of L-glutamate, L-glutamine and glycine content in brain, cerebrospinal fluid and blood serum of patients affected by Alzheimer's disease.

Authors:  Tommaso Nuzzo; Andrea Mancini; Mattia Miroballo; Alessia Casamassa; Anna Di Maio; Giorgia Donati; Giulia Sansone; Lorenzo Gaetani; Federico Paolini Paoletti; Andrea Isidori; Paolo Calabresi; Francesco Errico; Lucilla Parnetti; Alessandro Usiello
Journal:  Amino Acids       Date:  2021-02-22       Impact factor: 3.520

8.  Cerebrospinal Fluid Alzheimer's Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort.

Authors:  Inger van Steenoven; Dag Aarsland; Daniel Weintraub; Elisabet Londos; Frédéric Blanc; Wiesje M van der Flier; Charlotte E Teunissen; Brit Mollenhauer; Tormod Fladby; Milica G Kramberger; Laura Bonanni; Afina W Lemstra
Journal:  J Alzheimers Dis       Date:  2016-08-18       Impact factor: 4.472

9.  cNEUPRO: Novel Biomarkers for Neurodegenerative Diseases.

Authors:  Philipp Spitzer; Hans Wolfgang Klafki; Kaj Blennow; Luc Buée; Hermann Esselmann; Sanna-Kaisa Herruka; Connie Jimenez; Peter Klivenyi; Piotr Lewczuk; Juan Manuel Maler; Katrin Markus; Helmut E Meyer; Chris Morris; Thorsten Müller; Markus Otto; Lucilla Parnetti; Hilkka Soininen; Susanna Schraen; Charlotte Teunissen; Laszlo Vecsei; Henrik Zetterberg; Jens Wiltfang
Journal:  Int J Alzheimers Dis       Date:  2010-09-19

10.  The chemokine CXCL13 is a prognostic marker in clinically isolated syndrome (CIS).

Authors:  Johannes Brettschneider; Anne Czerwoniak; Makbule Senel; Lubin Fang; Jan Kassubek; Elmar Pinkhardt; Florian Lauda; Tamara Kapfer; Sarah Jesse; Vera Lehmensiek; Albert C Ludolph; Markus Otto; Hayrettin Tumani
Journal:  PLoS One       Date:  2010-08-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.